Earnings History Data for Ascendis Pharma A/S (ASND) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology, central nervous system disorders, infectious diseases and diabetes. Its technology includes TransCon which develop prodrug therapies. Ascendis Pharma A/S is based in Denmark.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
14-11-2024	AH		ASND	Ascendis Pharma A/S	7,230	-1.89	-1.54	-3.12	Ascendis Pharma GAAP EPS of -€1.72, revenue of €57.83M [11/14/2024 4:16 PM]	126.69	2.41 (1.94%)	122.65	-1.63 (-1.31%)	90.13 - 161.00	1,307,543	460,000	193
Ascendis Pharma GAAP EPS of -€1.72, revenue of €57.83M [11/14/2024 4:16 PM] Ascendis Pharma Reports Third Quarter 2024 Financial Results [2024-11-14 04:01PM]
03-09-2024	PM		ASND	Ascendis Pharma	8,032	-2.05	-1.54	0.00	Ascendis Pharma GAAP EPS of -€1.91, revenue of €36M; revises FY24 revenue outlook [9/4/2024 1:43 AM]	119.23	-15.45 (-11.47%)	116.89	-17.79 (-13.21%)	85.29 - 161.00	2,951,011	350,000	90,474
Ascendis and Royalty Pharma enter into $150M royalty funding agreement [9/3/2024 5:17 PM] Ascendis Pharma GAAP EPS of -€1.91, revenue of €36M; revises FY24 revenue outlook [9/4/2024 1:43 AM] Ascendis stock falls 12% amid lowered outlook, royalty deal [9/4/2024 11:06 AM]
02-05-2024	AH		ASND	Ascendis Pharma A/S	7,930	-2.48	-1.57	-2.12	Ascendis Pharma reports Q1 results [5/2/2024 4:41 PM]	137.63	-3.47 (-2.46%)	141.50	0.40 (0.28%)	83.75 - 161.00	460,644	290,000	17,130
Ascendis Pharma reports Q1 results [5/2/2024 4:41 PM]
07-02-2024	AH		ASND	Ascendis Pharma A/S	8,180	-1.66	-2.15	-3.78	Ascendis Pharma GAAP EPS of -€1.54, revenue of €137.7M [2/7/2024 4:41 PM]	139.26	-0.03 (-0.02%)	139.29	0.0 (0.00%)	64.33 - 144.95	423,986	450,000	6,322
Ascendis Pharma GAAP EPS of -€1.54, revenue of €137.7M [2/7/2024 4:41 PM]
07-11-2023	AH		ASND	Ascendis Pharma A/S	5,410	-3.12	-2.63	-3.05	Ascendis Pharma GAAP EPS of -$2.88 misses by $0.39, revenue of $48.03M misses by $2.76M [11/7/2023 4:24 PM]	94.97	-1.19 (-1.23%)	96.60	0.45 (0.47%)	64.33 - 134.52	261,417	420,000	90,563
Ascendis Pharma GAAP EPS of -€2.88 misses by €0.39, revenue of €48.03M misses by €2.76M [11/7/2023 4:24 PM]
05-09-2023	AH		ASND	Ascendis Pharma A/S	5,600	-2.35	-2.68	-1.54	Ascendis Pharma GAAP EPS of -€2.16, revenue of €47.39M [9/5/2023 4:23 PM]	104.28	4.54 (4.55%)	103.00	3.26 (3.27%)	64.33 - 134.52	804,810	230,000	67,130
Ascendis Pharma GAAP EPS of -€2.16, revenue of €47.39M [9/5/2023 4:23 PM]
27-04-2023	AH	4:00 PM ET (Apr 27)	ASND	Ascendis Pharma A/S	4,480	-2.12	-2.84	-2.48	Ascendis Pharma reports Q1 results [4/27/2023 4:03 PM]	76.98	0.54 (0.71%)	75.73	-1.25 (-1.62%)	61.58 - 134.52	951,349	610,000	614
Ascendis Pharma reports Q1 results [4/27/2023 4:03 PM]
16-02-2023	AH	4:00 PM ET (Feb 16)	ASND	Ascendis Pharma A/S	6,330	-3.78	-2.50	-2.14	Ascendis Pharma GAAP EPS of -€10.40, revenue of €51.17M [2/16/2023 4:07 PM]	116.79	5.43 (4.88%)	105.00	-6.36 (-5.71%)	61.58 - 134.52	517,175	250,000	1,810
Ascendis Pharma GAAP EPS of -€10.40, revenue of €51.17M [2/16/2023 4:07 PM]
02-11-2022	AH	4:00 PM ET (Nov 2)	ASND	Ascendis Pharma A/S	6,420	-3.05	-2.48	-1.73	Ascendis Pharma GAAP EPS of -€3.03, revenue of €15.29M [11/2/2022 4:55 PM]	118.92	4.98 (4.37%)	113.94	0.0 (0.00%)	61.58 - 166.88	784,140	420,000	320
Ascendis Pharma GAAP EPS of -€3.03, revenue of €15.29M [11/2/2022 4:55 PM] Ascendis Pharma Reports Third Quarter 2022 Financial Results [Nov-02-22 04:01PM]
10-08-2022	AH	4:00 PM ET (Aug 10)	ASND	Ascendis Pharma A/S	5,040	-1.54	-2.11	-3.01	Ascendis Pharma GAAP EPS of -€1.46 beats by €0.69, revenue of €6.16B beats by $6.15B [8/10/2022 4:30 PM]	104.85	9.71 (10.21%)	95.14	0.0 (0.00%)	61.58 - 178.71	977,984	610,000	131,124
Ascendis Pharma GAAP EPS of -€1.46 beats by €0.69, revenue of €6.16B beats by $6.15B [8/10/2022 4:30 PM] Ascendis Pharma Q2 results beat buoyed by strong sales of growth hormone drug Skytrofa [8/11/2022 11:18 AM] Ascendis Pharma Presents a Mixed Technical Picture Ahead of Earnings [Aug-09-22 08:06AM] Ascendis Pharma A/S Reports Second Quarter 2022 Financial Results [Aug-10-22 04:01PM]
11-05-2022	AH	4:00 PM ET (May 11)	ASND	Ascendis Pharma A/S	4,490	-2.48	-2.25	-1.41	Ascendis Pharma GAAP EPS of -€2.21 misses by €0.05, revenue of €6.83M beats by €1.98M [5/11/2022 4:16 PM]	79.89	1.81 (2.32%)	67.00	-11.08 (-14.19%)	61.58 - 178.71	3,148,184	700,000	18,611
Ascendis Pharma GAAP EPS of -€2.21 misses by €0.05, revenue of €6.83M beats by €1.98M [5/11/2022 4:16 PM] Ascendis Pharma slides after Street analysts cut price target over SKYTROFA revenue miss [5/12/2022 1:21 PM] Why Ascendis Pharma (ASND) Might Surprise This Earnings Season [May-11-22 02:40AM] Vermilion Energy (VET) to Report Q1 Earnings: What's in Store? [May-10-22 11:13AM] Ascendis Pharma A/S Reports First Quarter 2022 Financial Results [May-11-22 04:01PM] Ascendis Slammed After Growth Hormone Drug Faces An Unexpected Challenge [May-12-22 09:48AM] Ascendis Slammed As Its Newest Drug Faces An Unexpected Challenge [May-12-22 11:52AM]
02-03-2022	AH	4:00 PM ET (Mar 2)	ASND	Ascendis Pharma	6,392	-2.14	-2.57	0.00	Ascendis Pharma GAAP EPS of $7.00 beats by €15.44, revenue of €7.77M misses by $0.13M [3/2/2022 4:10 PM]	105.34	-1.14 (-1.07%)	98.60	-7.88 (-7.40%)	102.00 - 178.71	253,217	300,000	19,222
Ascendis Pharma A/S Reports Full Year 2021 Financial Results and Provides a Business Update [Mar-02-22 04:01PM] Should You Buy Ascendis Pharma (ASND) Ahead of Earnings? [Mar-03-22 09:30AM]
10-11-2021	AH	4:10 PM ET (Nov 10)	ASND	Ascendis Pharma A/S	9,140	-1.73	-2.60	-2.70	Ascendis Pharma reports Q3 results [11/10/2021 4:25 PM]	155.09	2.03 (1.33%)	153.06	0.0 (0.00%)	109.36 - 183.98	89,703	170,000	2,287
Ascendis Pharma reports Q3 results [11/10/2021 4:25 PM] Ascendis Pharma A/S Presents New Non-Clinical Data for TransCon TLR7/8 Agonist Oncology Program at SITC 2021 [Nov-09-21 08:00AM] Were Hedge Funds Right About Ascendis Pharma A/S (ASND)? [Nov-10-21 12:35AM] Ascendis Pharma A/S Reports Third Quarter 2021 Financial Results [Nov-10-21 04:01PM] Ascendis Pharma A/S (ASND) Q3 2021 Earnings Call Transcript [Nov-10-21 10:00PM]
25-08-2021	AH	4:00 PM ET (Aug 25)	ASND	Ascendis Pharma A/S	6,570	-3.01	-2.75	-2.17	Ascendis Pharma EPS beats by $0.14 [8/25/2021 4:23 PM]	149.09	25.43 (20.56%)	150.63	26.97 (21.80%)	109.36 - 183.98	2,136,992	200,000	57,137
Ascendis adds over 20% most in over two years as regulatory win prompt higher targets [8/26/2021 12:13 PM] Ascendis Pharma A/S Announces U.S. Food and Drug Administration Approval of SKYTROFA® (lonapegsomatropin-tcgd), the First Once-weekly Treatment for Pediatric Growth Hormone Deficiency [Aug-25-21 03:24PM] Ascendis Pharma A/S Reports Second Quarter 2021 Financial Results [Aug-25-21 04:12PM] These 2 Stocks Soared Double Digits After Hours [Aug-25-21 06:20PM] 22 Stocks Moving in Thursday's Pre-Market Session [Aug-26-21 07:12AM] Ascendis Stock Surges To 6-Month High; FDA Approval Lands It In A Major Market [Aug-26-21 11:11AM] Ascendis Stock Jumps as FDA Clears Growth-Hormone Treatment [Aug-26-21 07:28AM] Here's Why Ascendis Pharma Shares Are Surging Higher Today [Aug-26-21 02:13PM] See Why Ascendis Pharma Stock Is Shining On Thursday [Aug-26-21 11:34AM] Mid-Day Market Update: Dow Tumbles Over 100 Points; Ascendis Pharma Shares Spike Higher [Aug-26-21 12:13PM]
27-05-2021	AH	4:00 PM ET (May 27)	ASND	Ascendis Pharma A/S	7,140	-1.41	-2.06	-1.46	Ascendis Pharma reports Q1 results [5/27/2021 4:03 PM]	134.00	-2.19 (-1.61%)	136.19	0.0 (0.00%)	119.11 - 183.98	238,156	190,000	893
Ascendis Pharma reports Q1 results [5/27/2021 4:03 PM] Ascendis Pharma A/S Reports First Quarter 2021 Financial Results [May-27-21 04:01PM] Ascendis Pharma A/S Invites the Public to Attend A Story of Courage: Living with Hypoparathyroidism in Support of World Hypopara Awareness Day on June 1, 2021 [May-28-21 07:05AM] Ascendis Pharma A/S (ASND) Q1 2021 Earnings Call Transcript [May-28-21 01:00PM]
10-03-2021	AH	4:00 PM ET (Mar 10)	ASND	Ascendis Pharma A/S	7,590	-3.15	-1.84	-1.88		149.46	5.47 (3.80%)	143.99	0.0 (0.00%)	92.00 - 183.98	130,101	232,100	3,913
Ascendis Pharma reports FY results [3/10/2021 4:16 PM] Ascendis Pharma initiated with a buy at Stifel [3/11/2021 11:11 AM] Earnings Preview for Ascendis Pharma [Mar-09-21 10:16AM] Ascendis Pharma A/S Announces Seven Presentations at ENDO 2021, Demonstrating Commitment to People with Rare Endocrine Diseases [Mar-10-21 07:05AM] Ascendis Pharma A/S Reports Full Year 2020 Financial Results [Mar-10-21 04:01PM] Ascendis Pharma A/S (ASND) Q4 2020 Earnings Call Transcript [Mar-11-21 05:30AM]
11-11-2020	AH	4:00 PM ET (Nov 11)	ASND	Ascendis Pharma A/S	8,990	-2.70	-1.80	-0.59	Ascendis Pharma reports Q3 results [11/11/2020 4:06 PM]	166.37	6.37 (3.98%)	160.00	0.0 (0.00%)	92.00 - 178.26	201,664	150,823	6,498

27-08-2020	AH	4:00 PM ET (Aug 27)	ASND	Ascendis Pharma A/S	7,360	-2.17	-1.66	-1.40	Ascendis Pharma EPS misses by €0.50, misses on revenue [8/27/2020 4:13 PM]	137.59	-0.23 (-0.17%)	0.0	0.0 (0.00%)	90.06 - 158.93	76,975	137,295	0

19-05-2020	AH	4:00 PM ET (May 19)	ASND	Ascendis Pharma A/S	6,710	-1.46	-1.49	-1.41	Ascendis Pharma EPS beats by €0.01, beats on revenue [5/19/2020 4:07 PM]	146.20	3.01 (2.10%)	142.50	-3.66 (-2.50%)	90.06 - 150.00	360,017	260,659	0